Close Menu
Merck, Caprotec Collaborate on Protein-Drug Interaction Research
 
Caprotec Bioanalytics said this week it and Merck KGaA reached an agreement for use of Caprotec’s Capture Compound Mass Spectrometry technology for the identification of relevant protein-drug molecule interactions. Merck KGaA was acting on behalf of its Merck Serono division in reaching the agreement with Caprotec.
 
The technology will be applied to an undisclosed Merck Serono research project.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.